Eczema epidemiology and demographics

Eczema Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Eczema from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Social Impact

Future or Investigational Therapies

Case Studies

Case #1

Eczema On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Eczema

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Eczema

CDC on Eczema

Eczema in the news

Blogs on Eczema

Directions to Hospitals Treating Eczema

Risk calculators and risk factors for Eczema

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief:  Edzel Lorraine Co, D.M.D., M.D.

## Overview

[edit | edit source]

In the United States, eczema has a prevalence of 10.7% in children and 7.2% in adults. [1] [2] Eczema has more predilection in males. [3]

## Eczema Epidemiology and Demographics

[edit | edit source]

* A recent study showed that persistence of disease 8 years from the onset is noted in 20% of children.[4]
* Eczema has more predilection in males. [3]
* In the United States, eczema has a prevalence of 10.7% in children and 7.2% in adults. [1] [2]
* Prevalence of eczema has plateaued in high-income countries, with low- and middle-income countries still having increasing cases. [5]

## References

[edit | edit source]

1. ↑ 1.0 1.1 Shaw TE, Currie GP, Koudelka CW, Simpson EL (2011). "Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health". J Invest Dermatol. 131 (1): 67–73. doi:10.1038/jid.2010.251. PMC 3130508. PMID 20739951.CS1 maint: Multiple names: authors list (link)
2. ↑ 2.0 2.1 Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC (2015). "Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study". J Invest Dermatol. 135 (1): 56–66. doi:10.1038/jid.2014.325. PMID 25078665.CS1 maint: Multiple names: authors list (link)
3. ↑ 3.0 3.1 Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group (2007). "A population-based survey of eczema prevalence in the United States". Dermatitis. 18 (2): 82–91. doi:10.2310/6620.2007.06034. PMID 17498413.CS1 maint: Multiple names: authors list (link)
4. ↑ Kim JP, Chao LX, Simpson EL, Silverberg JI (2016). "Persistence of atopic dermatitis (AD): A systematic review and meta-analysis". J Am Acad Dermatol. 75 (4): 681–687.e11. doi:10.1016/j.jaad.2016.05.028. PMC 5216177. PMID 27544489.CS1 maint: Multiple names: authors list (link)
5. ↑ Baurecht H, Rühlemann MC, Rodríguez E, Thielking F, Harder I, Erkens AS; et al. (2018). "Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration". J Allergy Clin Immunol. 141 (5): 1668–1676.e16. doi:10.1016/j.jaci.2018.01.019. PMID 29421277.CS1 maint: Multiple names: authors list (link)